GLP-1s and Muscle Loss; 'Ozempic Personality'; Acromegaly and Cancer Risk

(MedPage Today) — Real-world data suggests that the dual GLP-1/GIP receptor agonist tirzepatide (Mounjaro, Zepbound) was associated with greater weight loss, but also muscle loss, compared to semaglutide (Ozempic, Wegovy), according to a doctor…